Form 8-K - Current report:
SEC Accession No. 0001140361-24-038472
Filing Date
2024-08-26
Accepted
2024-08-26 08:03:45
Documents
15
Period of Report
2024-08-26
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20034807_8k.htm   iXBRL 8-K 25913
2 EXHIBIT 99.1 ef20034807_ex99-1.htm EX-99.1 30640
6 image00001.jpg GRAPHIC 4319
  Complete submission text file 0001140361-24-038472.txt   205374

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vcel-20240826.xsd EX-101.SCH 3856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vcel-20240826_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vcel-20240826_pre.xml EX-101.PRE 16038
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20034807_8k_htm.xml XML 4044
Mailing Address 64 SIDNEY ST. CAMBRIDGE MA 02139
Business Address 64 SIDNEY ST. CAMBRIDGE MA 02139 7349305555
Vericel Corp (Filer) CIK: 0000887359 (see all company filings)

EIN.: 943096597 | State of Incorp.: MI | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35280 | Film No.: 241237822
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)